Key result
Targeting DDX3 helicase shows promise for suppressing HIV-1 replication and overcoming viral drug resistance.
Why the study?
High mutation and replication rates of HIV-1 lead to drug resistance against therapies targeting viral proteins, motivating exploration of cellular cofactors as new targets.
Answers are grounded in this paper and cite their sources.
Targeting host cellular cofactors like DDX3 represents a novel strategy to inhibit HIV-1 replication and potentially overcome viral drug resistance.
Compounds currently used for the treatment of HIV-1 Infections are targeted to viral proteins. However, the high intrinsic mutation and replication rates of HIV-1 often lead to the emergence of drug resistant strains and consequent therapeutic failure. On this basis, cellular cofactors represent attractive new targets for HIV-1 chemotherapy, since targeting a cellular factor that is required for viral replication should help to overcome the problem of viral resistance. We and others have recently reported the identification of compounds suppressing HIV-1 replication by targeting the cellular DEAD-box helicase DDX3. These results provide a proof-of-principle for the feasibility of blocking HIV-1 infection by rendering the host cell environment less favorable for the virus. The rationale for such an approach and its implications in potentially overcoming the problem of drug resistance related to drugs targeting viral proteins will be discussed in the context of the known cellular functions of the DEAD-box helicase DDX3.
No takes yet. Share an insight, caveat, or question.
Garbelli et al. (2011) conducted a review in HIV-1 Infections. Compounds targeting the cellular DEAD-box helicase DDX3 was evaluated. Targeting the cellular DEAD-box helicase DDX3 represents a promising strategy to suppress HIV-1 replication and potentially overcome viral drug resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: